I think it is possible after Angelman but more importantly a favourable outcome in the post-phase 2 meeting with the FDA for Phelan McDermid syndrome which is slated for this quarter.
- Agreeance on what the protocol will be for the Phase 3 study (which would be similar for other indications)
- A modification/simplification for the protocol for the subsequent Phase 2 studies in other indications
- Subsequent to the meeting - the additional Phase 2 indications will be announced and will move as soon as possible
This gives a clear roadmap for commercialising NNZ-2591.
I think it is possible after Angelman but more importantly a...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.02 |
Change
0.080(0.62%) |
Mkt cap ! $1.664B | |||
| Open | High | Low | Value | Volume |
| $13.23 | $13.35 | $12.99 | $5.557M | 423.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1588 | $13.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.06 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |